Abstract
Introduction: Since 2017, NICE has approved the first line use of Cyclin Dependent Kinase 4/6 Inhibitors (CDKis) for hormone receptor positive and HER2 negative locally advanced (LABC) or metastatic breast cancer (MBC). Uptake amongst units is variable. CDKis are currently only licensed in conjunction with an aromatase inhibitor or Fulvestrant. Alternative treatments include endocrine monotherapy and/or chemotherapy. This retrospective audit aims to quantify the uptake of CDKis at University Hospital Birmingham (UHB) Trust, and assess variations, if any, compared to the expected uptake of 60% determined by NICE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
